|
|
||||||||
J Thorac Cardiovasc Surg 2005;130:591-592
© 2005 The American Association for Thoracic Surgery
Brief Communication |
a Department of Cardiology and Intensive Care Medicine, LKH-Graz-West, Graz, Austria
b Institute of Pathology, Medical University Graz, Graz, Austria
c Department of Cardiac Surgery, Medical University Graz, Graz, Austria
Received for publication December 16, 2004; accepted for publication December 21, 2004. * Address for reprints: Dr Herwig W Schuchlenz, Department of Cardiology and Intensive Care Medicine, LKH-Graz-West, A-8020 Graz, Austria (Email: herwig.schuchlenz{at}lkh-grazwest.at).
Despite the lack of consensus regarding the optimal management strategy after a presumed paradoxic embolism through a patent foramen ovale (PFO), percutaneous device closure is used frequently for secondary prevention in these patients.
1,2
This report describes the first histologically proven case of a symptomatic device thrombosis as a result of a chronic inflammatory foreign body response to a PFO closure device.
Clinical Summary
A 48-year-old woman presented to the emergency department with signs of a completed stroke. Five hours before admission, hemihypesthesia and weakness developed on her right side. She had received a percutaneous occlusion (28-mm CardioSEAL device; NMT Medical, Boston, Mass) of her PFO after a cryptogenic cerebrovascular event 2 months earlier. She was discharged and prescribed Aspirin (100 mg once daily) the day after the intervention. Laboratory tests for hypercoagulable states showed normal results during the first evaluation and on readmittance. Neither diffusion-weighted magnetic resonance imaging of the brain nor ultrasound examination of the brain supplying arteries revealed pathologic findings. An urgent transesophageal echocardiographic study demonstrated 2 large pedunculated thrombi on the left atrial disk of the CardioSEAL device (Figure 1). An electrocardiogram showed ectopic atrial beats. The patient was first administered Clopidogrel (75 mg) and low-molecular heparin (80 mg enoxaparin twice/day). After 10 days she was readmitted with the same symptoms. The transesophageal echocardiogram documented the known thrombi, which had increased in size. The device and thrombotic material were surgically removed, and the defect was closed without complications. Histologic examination detected a marked foreign body reaction at the Dacron-tissue interface (Figure 2).
|
|
At present, the CardioSEAL and Amplatzer (AGA Medical Corp, Golden Valley, Minn) occluders are approved under humanitarian device regulations by the US Food and Drug Administration for PFO closure in patients who have had multiple strokes and in whom conventional drug therapy with warfarin has failed. The most commonly reported complications after percutaneous device implantation are atrial fibrillation in approximately 6% and thrombus formation on the device ranging from 7% to 22% in patients with the CardioSEAL device, compared with 0% in patients with the Amplatzer device.
1,2
Device design may therefore have an impact on tissue reaction.
The CardioSEAL device consists of 2 sets of flexible metallic arms (alloy of nickel and titanium [nitinol]) to which polyester fabric (Dacron) is attached. The Amplatzer device is a self-centering double disc made from nitinol wire frame filled with polyester fabric.
A fast endothelialization without thrombus formation or marked foreign body reaction is reported for both devices. However, histologic information about the tissue reaction after device implantation is limited to animal studies.
3,4
Various in vitro and in vivo studies demonstrated that Dacron may generate a severe implant-host reaction that may induce thrombus formation or trigger atrial arrhythmias as reported in this case.
5
Although animal studies usually show uncomplicated tissue ingrowth and endothelialization after device implantation, our case documents that tissue reaction to the CardioSEAL occluder may be unpredictable in human hearts and may expose patients to a life-threatening situation. Further research should be focused on the application of more biocompatible materials to avoid the consequences of foreign body response.
References
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |